Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease
Genetics in Medicine Open · 2026 · 4 · 103478
DOI: 10.1016/j.gimo.2025.103478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026. Verfasst von Ankit K Desai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lysosomal Disease Network, National Institutes of Health, Children's Hospital of Pittsburgh.
Abstract (Originalsprache)
Purpose
To assess the benefits of early enzyme replacement therapy (ERT) in patients with infantile-onset Pompe disease (IOPD).
Methods
A retrospective chart review of 17 IOPD (7 cross-reactive immunologic material [CRIM]-negative and 10 CRIM positive) who initiated ERT (alglucosidase alfa) ≤4 weeks of age and had ≥18 months follow-up was performed.
Results
Patients received starting doses of 20 mg/kg/every other week (n = 11), 20 mg/kg/week (n = 3), or 40 mg/kg/week (n = 3). Six CRIM-negative and 2 patients who were CRIM positive received immune tolerance induction (ITI) with Rituximab+Methotrexate+intravenous immunoglobulin. Five patients who were CRIM positive received transient low-dose methotrexate. All CRIM-negative patients were immune tolerant. Three patients who were CRIM positive developed high-sustained antibody titers (HSAT); 2 were immune tolerant after bortezomib-based ITI. One patient who was CRIM positive developed HSAT, was invasively ventilated, and succumbed at age 5.2 years. At the most recent follow-up (MRFU; 3.1-18.4 years), 16 patients were alive, ambulatory, feeding orally, invasive ventilator-free, and receiving high-dose ERT (median lifelong dose 2.76X; 1.36-4.00). All patients experienced left ventricular mass index and Glc4 reductions and for a subset, biomarkers were within normal limits at MRFU (left ventricular mass index:16/17, AST:9/17, CK:5/17, and Glc4:5/16).
Conclusion
These data highlight the benefits of early ERT initiation and ITI, along with high-dose ERT. Despite early treatment, patients with IOPD remain at risk of developing HSAT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC.
- Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA.
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA.
- Advanced Medical Genetics, Maria Fareri Children's Hospital at WMC Health, Hawthorne, NY.
- Department of Pathology and Pediatrics, New York Medical College, Valhalla, NY.
- East Tennessee Children's Hospital, Knoxville, TN.
Förderung
- Lysosomal Disease Network
- National Institutes of Health
- Children's Hospital of Pittsburgh
- National Institute of Neurological Disorders and Stroke
- Cincinnati Children's Hospital Medical Center
- National Center for Advancing Translational Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
- Rare Diseases Clinical Research Network
Zitieren
APA
Desai, A. K., Rodriguez-Rassi, E., Parikh, S., Russo, R. S., Kronn, D., Hamm, J. A., Chang, I. J., Ortiz, D., McPheron, M., Lydigsen, H., DeArmey, S., Young, S. P., & Kishnani, P. S. (2026). Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease. Genetics in Medicine Open, 4, 103478. https://doi.org/10.1016/j.gimo.2025.103478
Vancouver
Desai AK, Rodriguez-Rassi E, Parikh S, Russo RS, Kronn D, Hamm JA, et al. Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease. Genetics in Medicine Open. 2026;4:103478. doi:10.1016/j.gimo.2025.103478
BibTeX
@article{Desai2026,
author = {Desai, Ankit K and Rodriguez-Rassi, Eleanor and Parikh, Suhag and Russo, Rossana Sanchez and Kronn, David and Hamm, J Austin and Chang, Irene J and Ortiz, Damara and McPheron, Molly and Lydigsen, Holly and DeArmey, Stephanie and Young, Sarah P and Kishnani, Priya S},
title = {Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease},
journal = {Genetics in Medicine Open},
year = {2026},
volume = {4},
pages = {103478},
doi = {10.1016/j.gimo.2025.103478}
}
EUVIMED